Madrigal Pharmaceuticals Hits New 52-Week High of $469.95

Madrigal Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 469.95 on November 4, 2025. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 10,115 million.
Over the past year, Madrigal Pharmaceuticals has demonstrated impressive growth, with a remarkable 74.45% increase in stock performance, significantly outperforming the S&P 500, which recorded a 19.89% gain during the same period. The company has also reported outstanding results, including a staggering 1353.76% growth in net sales, with the latest quarterly net sales reaching USD 212.8 million.

Despite being a loss-making entity, Madrigal's financial metrics indicate a strong market position, with high institutional holdings at 100%, reflecting confidence from sophisticated investors. The company has consistently delivered positive results over the last two quarters, showcasing its potential in the competitive pharmaceutical landscape. As it continues to build on its recent successes, Madrigal Pharmaceuticals remains a noteworthy player in the industry.